TABLE 2.
Number of episodes of overt hepatic encephalopathy in the patients with or without improvement of SMI, SATI and VATI at the end of follow‐up
|
No SMI improvement (n = 13) |
SMI improvement (n = 22) |
P value |
No SATI increase (n = 7) |
SATI increase (n = 28) |
P value |
No VATI decrease (n = 11) |
VATI decrease (n = 24) |
P value |
|
|---|---|---|---|---|---|---|---|---|---|
|
n° episodes HE post‐TIPS |
2 (1‐3) | 1 (0‐1) | .01 | 3 (0‐3) | 1 (0‐1) | .04 | 2 (0‐3) | 1 (0‐2) | .22 |
| n° episodes HE first month post‐TIPS | 1 (0‐2) | 1 (0‐1) | .49 | 1 (0‐2) | 1 (0‐1) | .2 | 1 (0‐2) | 1 (0‐1) | .59 |
| n° episodes HE the months after | 1 (0‐2) | 0 (0‐0) | .004 | 1 (0‐2) | 0 (0‐0) | .01 | 0 (0‐2) | 0 (0‐1) | .14 |
| Venous plasma ammonia (μg/dL) | 82 (40‐134) | 42 (31‐76) | .02 | 58 (31‐112) | 44 (32‐104) | .93 | 79 (22‐134) | 44 (31‐65) | .12 |
| Follow‐up (months) | 11 (7‐31) | 13 (8‐22) | .7 | 18.5 (6‐56) | 10 (8‐22) | .64 | 11 (6‐27) | 11 (8‐22) | .76 |
The comparison between the groups of patients (no SMI improvement and SMI improvement; no SATI increase and SATI increase; no VATI decrease and VATI decrease) was performed by unpaired Student t test or Mann‐Whitney test, when necessary. Data are expressed as median and interquartile range (IQR).